Национален План За Борба С Рака В Република България 2027

Objectives

Bulgaria’s National Cancer Control Plan to 2027 seeks to establish an integrated, accessible and patient-oriented oncology system spanning prevention, screening, innovative diagnosis, treatment, care and improved quality of life, aligned with accepted European and global standards and contributing to Europe’s Beating Cancer Plan.[1][2]It frames cancer as a major societal and health-system priority requiring a contemporary approach based on new technologies, research, innovation and sustainable services.[1][3]

• Modernise cancer control through patient-centred technologies, research, innovation, a renewed national oncology network and comprehensive cancer centres.[4][5][6]
• Prevent cancer by improving health literacy, supporting healthy diets and physical activity, reducing tobacco and harmful alcohol use, preventing infection-related cancers through vaccination, and limiting environmental and occupational carcinogenic exposures.[7][8][9][10]
• Expand early detection through organised, quality-assured screening for colorectal, breast, cervical, prostate and lung cancers, while developing integrated screening documentation and management systems.[4][11][12][13]
• Ensure high diagnostic standards through equitable access to imaging, pathology, molecular diagnostics, genetic counselling, reference centres and personalised assessment of inherited cancer risk.[14][15][16][17]
• Ensure high treatment standards through multidisciplinary, evidence-informed and increasingly personalised care, covering surgery, radiotherapy, systemic treatment, palliative and symptomatic care.[18][19][20]
• Improve quality of life for patients, families and carers through psycho-oncology, rehabilitation, social inclusion, palliative care, patient navigation, information and pharmaceutical support.[21][22][23][24]
• Tailor services to children and young people, people with rare tumours, and people with haematological malignancies, supported by specialised networks, registries, reference centres and long-term follow-up.[14][25][26][27]

Implementation

Implementation combines whole-of-government leadership, integrated care delivery, data-driven management, workforce development, European collaboration and phased service investment. The Council of Ministers provides overall coordination, while the Ministry of Health is responsible for implementation, intersectoral coordination and assessment of cross-sectoral effects; cooperation is envisaged with other ministries, state institutions, municipalities, academic bodies, healthcare providers, civil society and patient organisations.[28][29][30][31]

• Strengthen governance through national leadership with authority to set priorities and investments across the cancer continuum, alongside accountability, follow-up and transparent reporting.[31][3]
• Develop comprehensive oncology centres, multidisciplinary teams and coordinated pathways linking primary care, outpatient services, hospitals, diagnostic networks and specialist treatment providers.[32][33][34][20]
• Build workforce capacity through continuing education, revised university curricula, workforce-needs monitoring, expanded specialist roles and support for training in emerging diagnostic and treatment methods.[35][36][37][38]
• Establish an integrated national cancer registry and health-information infrastructure using electronic health records, clinical protocols and national statistics to support planning, screening analysis, risk assessment, outcome evaluation and international comparison.[39][40][41]
• Support research, clinical trials, real-world evidence, technology assessment, genomic and molecular profiling, and horizon scanning for diagnostic and therapeutic innovations.[42][43][44][45]
• Use targeted delivery mechanisms including general-practitioner engagement, invitations and reminders, public information, vaccination-support tools, organised screening registries, referral pathways and quality assurance.[8][46][11][47]
• Monitor implementation continuously through key indicators, compare progress with European Union averages and baseline values, report annually through the National Health Strategy 2030 framework, and conduct a final assessment after 2027 to update, extend or replace the plan if necessary.[48][49][50]
• Finance selected priorities through EU4Health, national funding and other European mechanisms, including allocations for the national oncology network, comprehensive oncology centres, workforce support, the oncology registry and data plan; the cited programme table gives a total allocation of 601 million Bulgarian lev.[51][52][53][54]

Monitoring & Evaluation

The Plan establishes a broad monitoring and evaluation architecture centred on key indicators, baseline comparisons, European Union benchmarking, routine data systems and periodic review. Implementation is to be monitored continuously, reported annually through the National Health Strategy 2030 health-status report, and assessed finally after the Plan period ends in 2027.[48][50]

• Monitor implementation through indicators on premature mortality, life expectancy and healthy life expectancy at age 65, overall cancer incidence, and incidence of selected cancers including stomach, colorectal, pancreatic, lung, breast, prostate and haematological malignancies.[48][49]
• Compare indicator values with European Union averages and assess progress through changes from baseline values and achieved results.[48][49]
• Use annual reporting under the National Health Strategy 2030 and conduct a final 2027 assessment to determine whether measures require revision, the Plan should be extended, or a successor plan should be prepared.[50]
• Coordinate implementation through a whole-of-government model, with the Council of Ministers responsible for overall governance and the Ministry of Health responsible for delivery, cross-sectoral impact assessment and intersectoral coordination.[28]
• Maintain an updated National Cancer Registry and integrated oncology information systems, drawing on electronic health records, treatment protocols and national statistics to support planning, surveillance, programme evaluation and international comparison.[39][40][41]
• Measure regional and site-specific cancer burden through newly diagnosed cases, people receiving treatment and mortality; assess prevention and screening programmes through years of life lost and public expenditure.[41]
• Track organised screening through coverage, public awareness, participation, quality assurance, completion of examinations and the proportion of cancers diagnosed at stages I and II.[12][55][13]
• Set selected service milestones, including 90% recognition of relevant oncology structures and personnel by 2027, full geographical coverage of modern diagnostic and treatment equipment by 2027, and access to comprehensive oncology centres for 90% of patients by 2030.[56][57][32]
• Monitor treatment outcomes, adverse reactions, patient satisfaction and quality of life, supported by multidisciplinary documentation, clinical-practice data collection and public availability of professional and scientific treatment-outcome information.[58][59][60][61]
• Apply programme-level quality assurance through screening registries, audit, accreditation, laboratory standards, participant follow-up and reporting. For regional screening centres, providers may report monthly, quarterly, semi-annually or annually, while the national administrator prepares an annual coverage report.[62][63][64]

Many action areas specify output targets and information-system functions but not complete methodologies, reporting templates, data-quality rules, independent scrutiny or sanctions for non-performance.[65][66][67][50]

Costing & Financing

The Plan identifies a mixed financing model involving national financing, European Union programmes, including EU4Health, and in some cases European Social Fund support. It provides substantial allocations for network development, information systems, screening, treatment access and patient-support services, but does not present a complete annual financing schedule, recurrent-cost model or quantified overall funding gap.[68][51][52][53][54]

• Allocate Bulgarian lev 6 million to restore, maintain and update the national cancer-control network; Bulgarian lev 3 million to comprehensive national oncology centres; Bulgarian lev 25 million to support health professionals; and Bulgarian lev 15 million to human-resource incentives.[51]
• Provide national financing of Bulgarian lev 10 million for an updated oncology registry and Bulgarian lev 7 million for a detailed oncology data and information plan.[52]
• Fund early-detection programmes, including Bulgarian lev 15 million for colorectal cancer, Bulgarian lev 30 million each for breast and lung cancer, Bulgarian lev 37.5 million for cervical cancer and Bulgarian lev 7.5 million for skin cancer.[69]
• Allocate Bulgarian lev 50 million for faster access to innovative oncology treatment, Bulgarian lev 35 million for accessible, timely and safe treatment, Bulgarian lev 30 million for psycho-oncology, Bulgarian lev 45 million for rehabilitation and additional-support care, and Bulgarian lev 10 million for an analytical decision-support system.[70][71]
• Record a total financial envelope of Bulgarian lev 601 million in the referenced financing table.[54]
• Recognise broader economic burden estimates of 587 million euros for cancer in Bulgaria in 2018, comprising healthcare, medicines, informal care and productivity losses.[72]
• Finance palliative care through compulsory health insurance within a regulated benefits package, with expenditure rising from Bulgarian leva 1,078,785 in 2018 to Bulgarian leva 1,825,227 in 2019.[73]
• Address identified financing constraints, including insufficient financing for histological assessment, uneven equipment distribution, lack of state financing for specified radiopharmaceutical therapies, incomplete reimbursement for paediatric treatment, and the absence of payment arrangements for terminal-stage care at home.[33][74][75][76]

Several measures identify public funding, project financing, reimbursement reform, cost-effectiveness assessment or resource needs without numerical budgets. These include molecular diagnostics, genetic services, radiopharmaceutical supply, multidisciplinary working, screening technologies and technology horizon scanning.[44][45][77][78][79][80]